New US Consensus Report supports Nevisense

· Consensus reached by top US clinicians assessing technologies for melanoma detection and management · The report concludes that the Nevisense AI-driven technology can significantly enhance early melanoma detectionSWEDEN, - Sept 02, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], pioneering prevention and prediction in dermatology announces that key US clinicians and scientists reached consensus on Nevisense and how it can significantly enhance the diagnostic assessment and clinical decision-making for early melanoma at point of care. Nevisense is an AI-driven, non-invasive